Analysts expect VIVUS, Inc. (NASDAQ:VVUS) to announce earnings of ($1.10) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for VIVUS’s earnings. VIVUS posted earnings of ($0.60) per share in the same quarter last year, which would suggest a negative year over year growth rate of 83.3%. The firm is expected to report its next earnings report on Tuesday, November 6th.

On average, analysts expect that VIVUS will report full-year earnings of ($4.40) per share for the current financial year. For the next financial year, analysts expect that the firm will post earnings of ($5.70) per share. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow VIVUS.

VIVUS (NASDAQ:VVUS) last issued its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.08). The business had revenue of $14.96 million during the quarter.

A number of equities analysts have weighed in on the company. Zacks Investment Research raised VIVUS from a “sell” rating to a “hold” rating in a research report on Thursday, September 13th. ValuEngine raised VIVUS from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 12th.

An institutional investor recently raised its position in VIVUS stock. Renaissance Technologies LLC boosted its holdings in VIVUS, Inc. (NASDAQ:VVUS) by 5.4% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,273,800 shares of the biopharmaceutical company’s stock after buying an additional 423,100 shares during the quarter. Renaissance Technologies LLC owned 7.79% of VIVUS worth $5,833,000 at the end of the most recent quarter.

NASDAQ:VVUS traded up $0.19 during mid-day trading on Friday, reaching $4.74. The company’s stock had a trading volume of 59,621 shares, compared to its average volume of 90,262. VIVUS has a 12-month low of $3.30 and a 12-month high of $9.90. The company has a debt-to-equity ratio of -10.60, a quick ratio of 4.26 and a current ratio of 4.93. The firm has a market cap of $46.98 million, a price-to-earnings ratio of -1.63 and a beta of 0.58.

VIVUS Company Profile

VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

Recommended Story: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on VIVUS (VVUS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with's FREE daily email newsletter.